Kezar Life Sciences Future Growth
Future criteria checks 2/6
Kezar Life Sciences is forecast to grow earnings and revenue by 7.4% and 48% per annum respectively while EPS is expected to grow by 12.8% per annum.
Key information
7.4%
Earnings growth rate
12.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 48.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -64 | N/A | -26 | 4 |
| 12/31/2025 | 3 | -69 | N/A | -38 | 6 |
| 12/31/2024 | N/A | -83 | N/A | -69 | 5 |
| 9/30/2024 | N/A | -96 | -76 | -76 | N/A |
| 6/30/2024 | 7 | -99 | -79 | -79 | N/A |
| 3/31/2024 | 7 | -101 | -85 | -84 | N/A |
| 12/31/2023 | 7 | -102 | -83 | -82 | N/A |
| 9/30/2023 | 7 | -88 | -81 | -79 | N/A |
| 6/30/2023 | N/A | -83 | -77 | -75 | N/A |
| 3/31/2023 | N/A | -74 | -68 | -66 | N/A |
| 12/31/2022 | N/A | -68 | -60 | -59 | N/A |
| 9/30/2022 | N/A | -64 | -56 | -54 | N/A |
| 6/30/2022 | N/A | -61 | -49 | -48 | N/A |
| 3/31/2022 | N/A | -58 | -48 | -47 | N/A |
| 12/31/2021 | N/A | -55 | -43 | -42 | N/A |
| 9/30/2021 | N/A | -51 | -41 | -41 | N/A |
| 6/30/2021 | N/A | -48 | -40 | -40 | N/A |
| 3/31/2021 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2020 | N/A | -42 | -37 | -37 | N/A |
| 9/30/2020 | N/A | -40 | -35 | -35 | N/A |
| 6/30/2020 | N/A | -38 | -34 | -34 | N/A |
| 3/31/2020 | N/A | -37 | -32 | -31 | N/A |
| 12/31/2019 | N/A | -35 | -30 | -30 | N/A |
| 9/30/2019 | N/A | -31 | -29 | -28 | N/A |
| 6/30/2019 | N/A | -28 | -25 | -24 | N/A |
| 3/31/2019 | N/A | -26 | -25 | -24 | N/A |
| 12/31/2018 | N/A | -23 | -22 | -21 | N/A |
| 9/30/2018 | N/A | -20 | -18 | -17 | N/A |
| 6/30/2018 | N/A | -16 | N/A | -15 | N/A |
| 3/31/2018 | N/A | -11 | N/A | -10 | N/A |
| 12/31/2017 | N/A | -9 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2KZ0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2KZ0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2KZ0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2KZ0's revenue (48% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 2KZ0's revenue (48% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2KZ0's Return on Equity is forecast to be high in 3 years time